KR102138904B1 - 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법 - Google Patents

파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법 Download PDF

Info

Publication number
KR102138904B1
KR102138904B1 KR1020197020747A KR20197020747A KR102138904B1 KR 102138904 B1 KR102138904 B1 KR 102138904B1 KR 1020197020747 A KR1020197020747 A KR 1020197020747A KR 20197020747 A KR20197020747 A KR 20197020747A KR 102138904 B1 KR102138904 B1 KR 102138904B1
Authority
KR
South Korea
Prior art keywords
subject
sample
fti
cancer
cxcl12
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020197020747A
Other languages
English (en)
Korean (ko)
Other versions
KR20190087661A (ko
Inventor
안토니오 구알베르토
캐서린 로즈 스콜츠
Original Assignee
쿠라 온콜로지, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/820,012 external-priority patent/US10137121B2/en
Application filed by 쿠라 온콜로지, 인크. filed Critical 쿠라 온콜로지, 인크.
Publication of KR20190087661A publication Critical patent/KR20190087661A/ko
Application granted granted Critical
Publication of KR102138904B1 publication Critical patent/KR102138904B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197020747A 2017-02-21 2018-02-21 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법 Expired - Fee Related KR102138904B1 (ko)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762461602P 2017-02-21 2017-02-21
US62/461,602 2017-02-21
US201762507749P 2017-05-17 2017-05-17
US62/507,749 2017-05-17
US201762519819P 2017-06-14 2017-06-14
US62/519,819 2017-06-14
US15/820,157 2017-11-21
US15/820,012 US10137121B2 (en) 2017-02-21 2017-11-21 Methods of treating cancer with farnesyltransferase inhibitors
US15/820,157 US9956215B1 (en) 2017-02-21 2017-11-21 Methods of treating cancer with farnesyltransferase inhibitors
US15/820,012 2017-11-21
US201762596653P 2017-12-08 2017-12-08
US62/596,653 2017-12-08
PCT/US2018/018989 WO2018156609A1 (en) 2017-02-21 2018-02-21 Methods of treating cancer with farnesyltransferase inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187032097A Division KR102003179B1 (ko) 2017-02-21 2018-02-21 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207021424A Division KR20200090982A (ko) 2017-02-21 2018-02-21 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법

Publications (2)

Publication Number Publication Date
KR20190087661A KR20190087661A (ko) 2019-07-24
KR102138904B1 true KR102138904B1 (ko) 2020-07-28

Family

ID=63253363

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197020747A Expired - Fee Related KR102138904B1 (ko) 2017-02-21 2018-02-21 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
KR1020187032097A Expired - Fee Related KR102003179B1 (ko) 2017-02-21 2018-02-21 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
KR1020207021424A Ceased KR20200090982A (ko) 2017-02-21 2018-02-21 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187032097A Expired - Fee Related KR102003179B1 (ko) 2017-02-21 2018-02-21 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
KR1020207021424A Ceased KR20200090982A (ko) 2017-02-21 2018-02-21 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법

Country Status (14)

Country Link
EP (3) EP3542800B1 (https=)
JP (1) JP7289795B2 (https=)
KR (3) KR102138904B1 (https=)
CN (4) CN109475550A (https=)
AU (3) AU2018225566B2 (https=)
BR (1) BR112019017375A2 (https=)
CA (1) CA3053795A1 (https=)
ES (2) ES2892157T3 (https=)
IL (1) IL268722A (https=)
MX (2) MX394077B (https=)
PH (1) PH12019501918A1 (https=)
SG (1) SG11201907594TA (https=)
TW (3) TWI738314B (https=)
WO (1) WO2018156609A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MX2020001207A (es) * 2017-08-07 2020-03-20 Kura Oncology Inc Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
US20220143006A1 (en) * 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2025224720A1 (en) * 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070093449A1 (en) 2005-10-14 2007-04-26 De Porre Peter M R Novel IV formulation of tipifarnib
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5693517A (en) 1987-06-17 1997-12-02 Roche Molecular Systems, Inc. Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions
US5310652A (en) 1986-08-22 1994-05-10 Hoffman-La Roche Inc. Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription
US5561058A (en) 1986-08-22 1996-10-01 Hoffmann-La Roche Inc. Methods for coupled high temperatures reverse transcription and polymerase chain reactions
WO1989001050A1 (en) 1987-07-31 1989-02-09 The Board Of Trustees Of The Leland Stanford Junior University Selective amplification of target polynucleotide sequences
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
IL100040A (en) 1990-11-13 1995-12-31 Siska Diagnostics Inc Nucleic acid amplification by two enzyme self-sustained sequence replication
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP1134293A3 (en) 1992-03-04 2004-01-07 The Regents of The University of California Comparative genomic hybridization (CGH)
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5686472A (en) 1992-10-29 1997-11-11 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5491063A (en) 1994-09-01 1996-02-13 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
US5571673A (en) 1994-11-23 1996-11-05 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
DE69725604T2 (de) 1996-12-20 2005-03-03 Sergazy Mynzhasarovich Adekenov VERFAHREN UND GERÄT ZUR HERSTELLUNG VPM LYOPHILISIERTEM 1ß, 10ß-EPOXY-13-DIMETHYLAMINO-GUAIA-3(4)-EN-6,12-OLID-HYDROCHLORID
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
TR200002059T2 (tr) 1998-01-16 2001-01-22 Takeda Chemical Industries, Ltd. Devamlı salınan bileşim, üretim yöntemi ve kullanımı.
CN1196336C (zh) 1998-03-05 2005-04-06 第一程式管理有限公司 数据通信系统
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
AU5086499A (en) 1998-07-01 2000-01-24 Merck & Co., Inc. Process for making farnesyl-protein transferase inhibitors
ID26987A (id) 1998-07-06 2001-02-22 Janssen Pharmaceutica Nv Inhibitor-inhibitor transferase protein farnesil dengan sifat-sifat peka terhadap sinar radiasi in vivo
ID27562A (id) 1998-08-27 2001-04-12 Pfizer Prod Inc Turunan-turunan kinolin-2-ona tersubstitusi alkunil yang berguna sebagai zat anti kanker
ES2237125T3 (es) 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.
US6927024B2 (en) 1998-11-30 2005-08-09 Genentech, Inc. PCR assay
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001042507A1 (en) 1999-12-09 2001-06-14 Advanced Research & Technology Institute Fluorescent in situ rt-pcr
US6838467B2 (en) 2000-02-24 2005-01-04 Janssen Pharmaceutica N. V. Dosing regimen
CA2439402A1 (en) 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
US7122799B2 (en) 2003-12-18 2006-10-17 Palo Alto Research Center Incorporated LED or laser enabled real-time PCR system and spectrophotometer
US20060078494A1 (en) * 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
EP2361263A1 (en) * 2008-10-31 2011-08-31 Abbott Biotherapeutics Corp. Use of anti-cs1 antibodies for treatment of rare lymphomas
EP2391211A4 (en) * 2009-01-30 2012-11-07 Genzyme Corp METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER
ES2705719T3 (es) * 2010-07-28 2019-03-26 Janssen Diagnostics Llc Métodos de determinación de la respuesta de la leucemia mieloide aguda al tratamiento con inhibidores de la farnesiltransferasa
EP2476441A1 (en) * 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
CN104039320B (zh) * 2011-11-09 2019-10-15 百时美施贵宝公司 血液恶性肿瘤用抗-cxcr4抗体的治疗
CN103787907B (zh) * 2014-02-17 2015-05-27 华东理工大学 作为法尼基转移酶抑制剂的苯胺类化合物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070093449A1 (en) 2005-10-14 2007-04-26 De Porre Peter M R Novel IV formulation of tipifarnib
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Thomas E. Witzig 외. Multi-institutional phase II of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood. Vol. 118(18), 2011년 11월*

Also Published As

Publication number Publication date
KR20190087661A (ko) 2019-07-24
WO2018156609A1 (en) 2018-08-30
KR20180123723A (ko) 2018-11-19
TW201834652A (zh) 2018-10-01
JP7289795B2 (ja) 2023-06-12
EP3542800B1 (en) 2022-06-01
JP2020508351A (ja) 2020-03-19
TW201929903A (zh) 2019-08-01
SG11201907594TA (en) 2019-09-27
KR20200090982A (ko) 2020-07-29
KR102003179B1 (ko) 2019-07-23
MX394077B (es) 2025-03-24
AU2019203548A1 (en) 2019-06-13
AU2018225566A1 (en) 2018-11-08
CN109999037A (zh) 2019-07-12
AU2019203548C1 (en) 2020-01-23
AU2018225566B2 (en) 2019-11-07
TWI738314B (zh) 2021-09-01
CN109475550A (zh) 2019-03-15
BR112019017375A2 (pt) 2020-03-31
EP3432883B1 (en) 2021-07-28
MX2022008843A (es) 2022-08-10
CN114796218A (zh) 2022-07-29
ES2892157T3 (es) 2022-02-02
TWI663974B (zh) 2019-07-01
EP3432883A1 (en) 2019-01-30
TW202031260A (zh) 2020-09-01
MX2019009821A (es) 2019-12-02
CN114712354A (zh) 2022-07-08
CA3053795A1 (en) 2018-08-30
PH12019501918A1 (en) 2020-06-01
AU2019246922A1 (en) 2019-10-31
TWI693074B (zh) 2020-05-11
EP4119142A1 (en) 2023-01-18
IL268722A (en) 2019-10-31
AU2019203548B2 (en) 2019-08-15
EP3542800A1 (en) 2019-09-25
ES2927228T3 (es) 2022-11-03

Similar Documents

Publication Publication Date Title
US10980793B2 (en) Methods of treating cancer with farnesyltransferase inhibitors
AU2019203548B2 (en) Methods of treating cancer with farnesyltransferase inhibitors
WO2017184968A1 (en) Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
US10806730B2 (en) Methods of treating cancer with farnesyltransferase inhibitors
US20170326133A1 (en) Methods of treating myelodysplastic syndrome with farnesyltransferase inhibitors
KR20200051601A (ko) 파르네실전달효소 억제제를 이용하여 암을 치료하는 방법
US20220168296A1 (en) Methods of treating cancer with farnesyltransferase inhibitors
HK40006709B (en) Methods of treating cancer with farnesyltransferase inhibitors
HK40006709A (en) Methods of treating cancer with farnesyltransferase inhibitors
HK1262842B (en) Methods of treating cancer with farnesyltransferase inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
A302 Request for accelerated examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302

St.27 status event code: A-1-2-D10-D17-exm-PA0302

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

Not in force date: 20230723

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230723

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000